Ligand Pharmaceuticals Incorporated Stock Price on November 7, 2024
| LGND Stock | USD 121.47 1.08 0.88% |
Below is the normalized historical share price chart for Ligand Pharmaceuticals Incorporated extending back to November 18, 1992. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Ligand Pharmaceuticals stands at 121.47, as last reported on the 1st of December, with the highest price reaching 124.34 and the lowest price hitting 120.01 during the day.
If you're considering investing in Ligand Stock, it is important to understand the factors that can impact its price. Ligand Pharmaceuticals appears to be very steady, given 3 months investment horizon. Ligand Pharmaceuticals has Sharpe Ratio of 0.12, which conveys that the firm had a 0.12% return per unit of risk over the last 3 months. We have found thirty technical indicators for Ligand Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please exercise Ligand Pharmaceuticals' Mean Deviation of 1.87, downside deviation of 2.67, and Risk Adjusted Performance of 0.0737 to check out if our risk estimates are consistent with your expectations.
The current year's Total Stockholder Equity is expected to grow to about 736 M, whereas Common Stock Shares Outstanding is forecasted to decline to about 16.2 M. . The current year's Price Earnings Ratio is expected to grow to 24.87, whereas Price To Sales Ratio is forecasted to decline to 9.20. Ligand Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 18th of November 1992 | 200 Day MA 92.3286 | 50 Day MA 109.707 | Beta 0.896 |
Ligand |
Sharpe Ratio = 0.1219
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | LGND | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.66 actual daily | 23 77% of assets are more volatile |
Expected Return
| 0.32 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Ligand Pharmaceuticals is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ligand Pharmaceuticals by adding it to a well-diversified portfolio.
Price Book 2.7286 | Enterprise Value Ebitda 21.7539 | Price Sales 15.1922 | Shares Float 18.5 M | Wall Street Target Price 140.25 |
Ligand Pharmaceuticals Main Headline on 7th of November 2024
Ligand Pharmaceuticals Releases FY24 Earnings Guidance by thelincolnianonline.com
Ligand Pharmaceuticals issued an update on its FY24 earnings guidance on Thursday morning. The company provided earnings per share guidance of 5.50-5.70 for the period, compared to the consensus estimate of 5.39. The company issued revenue guidance of 160-165 million, compared to the consensus revenue estimate of 156.29 million.
Ligand Pharmaceuticals Valuation on November 7, 2024
It is possible to determine the worth of Ligand Pharmaceuticals on a given historical date. On November 7, 2024 Ligand was worth 118.33 at the beginning of the trading date compared to the closed value of 129.9. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Ligand Pharmaceuticals stock. Still, in general, we apply an absolute valuation method to find Ligand Pharmaceuticals' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Ligand Pharmaceuticals where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Ligand Pharmaceuticals' related companies.
| Open | High | Low | Close | Volume | |
| 114.09 | 116.95 | 111.81 | 116.90 | 214,603 | |
11/07/2024 | 118.33 | 129.90 | 115.16 | 129.90 | 271,689 |
| 126.27 | 127.26 | 116.96 | 121.25 | 260,600 |
| Backtest Ligand Pharmaceuticals | | | Ligand Pharmaceuticals History | | | Ligand Pharmaceuticals Valuation | Previous | Next |
Ligand Pharmaceuticals Trading Date Momentum on November 7, 2024
| On November 08 2024 Ligand Pharmaceuticals Incorporated was traded for 121.25 at the closing time. The top price for the day was 127.26 and the lowest listed price was 116.96 . The trading volume for the day was 260.6 K. The trading history from November 8, 2024 was a factor to the next trading day price decrease. The trading delta at closing time against the next closing price was 6.66% . The trading delta at closing time against the current closing price is 14.65% . |
Ligand Pharmaceuticals Fundamentals Correlations and Trends
By evaluating Ligand Pharmaceuticals' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Ligand Pharmaceuticals' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Ligand financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Ligand Pharmaceuticals Stock history
Ligand Pharmaceuticals investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Ligand is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Ligand Pharmaceuticals will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Ligand Pharmaceuticals stock prices may prove useful in developing a viable investing in Ligand Pharmaceuticals
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 17.8 M | 16.2 M | |
| Net Loss | -38.4 M | -36.4 M |
Ligand Pharmaceuticals Quarterly Net Working Capital |
|
Ligand Pharmaceuticals Stock Technical Analysis
Ligand Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Ligand Pharmaceuticals Period Price Range
Low | December 1, 2024
| High |
0.00 | 0.00 |
Ligand Pharmaceuticals Incorporated cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Ligand Pharmaceuticals December 1, 2024 Market Strength
Market strength indicators help investors to evaluate how Ligand Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Ligand Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Ligand Pharmaceuticals stock market strength indicators, traders can identify Ligand Pharmaceuticals Incorporated entry and exit signals to maximize returns
Ligand Pharmaceuticals Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Ligand Pharmaceuticals' price direction in advance. Along with the technical and fundamental analysis of Ligand Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Ligand to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0737 | |||
| Jensen Alpha | 0.0366 | |||
| Total Risk Alpha | (0.22) | |||
| Sortino Ratio | 0.0362 | |||
| Treynor Ratio | 0.1525 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for Ligand Stock analysis
When running Ligand Pharmaceuticals' price analysis, check to measure Ligand Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ligand Pharmaceuticals is operating at the current time. Most of Ligand Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ligand Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ligand Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ligand Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |